FormalPara Key Points
Remimazolam has very low oral bioavailability of 1.2–2.2%.
Oral remimazolam up to 480 mg has no clear pharmacodynamic effects.
Alcohol dose-dependently increases exposure to remimazolam (up to two times).
Oral co-administration of alcohol and remimazolam shows mild pharmacodynamic effects.
Remimazolam has no potential for misuse in drug-facilitated sexual assaults.


Remimazolam is a new ultra-short-acting benzodiazepine being developed for intravenous procedural sedation, general anaesthesia, and sedation in the intensive care unit [1]. Benzodiazepines exhibit depressant properties on the central nervous system (CNS), resulting in psychomotor effects such as sedation, including the loss of consciousness and anterograde amnesia [2]. Such psychomotor effects pose the risk of benzodiazepines being misused in drug-facilitated sexual assaults, which usually happens after time spent in a party or a bar, and involves higher levels of drinking and self-reported intoxication with alcohol [3]. Toxicological data from victims, primarily women, showed that benzodiazepines are among the most common CNS-depressant drugs used in drug-facilitated sexual assaults and are found in the blood and urine of ~ 30% of cases across the USA, following alcohol and cannabis [4, 5]. Long- and intermediate-acting orally administered benzodiazepines such as flunitrazepam and diazepam are the most commonly used, followed by temazepam, lorazepam, and nitrazepam [6].

When co-ingested orally with alcohol, the psychomotor effects of many benzodiazepines are potentiated [7, 8], making this combination even more dangerous and prevalent in drug-facilitated sexual assaults. This potentiating effect is mediated via two different mechanisms. First, both alcohol and benzodiazepines bind to distinct binding sites on the GABAA receptor, ultimately leading to synergistic drug actions [9]. Moreover, like alcohol, many benzodiazepines are metabolised by cytochrome P450 enzymes [10], resulting in substrate competition and delayed clearance of benzodiazepines when co-ingested orally with alcohol [11]. Unlike other benzodiazepines, the conversion of remimazolam to its inactive metabolite is mediated by liver carboxylesterases 1A (CES-1A), with no contribution of cytochrome P450 enzymes. Nonetheless, alcohol is known to inhibit CES-1 function and can alter the disposition, efficacy, and safety of drugs metabolised by CES-1 [12]. Thus, potential exists for remimazolam’s sedative effect to be potentiated by alcohol via two distinct mechanisms, as is the case with other benzodiazepines. Therefore, a theoretical potential also exists for its misuse, alone or in combination with alcohol, in drug-facilitated sexual assaults.

We report here the results of two clinical trials designed to evaluate the bioavailability and pharmacokinetic/pharmacodynamic (PK/PD) profile of oral remimazolam, alone and in combination with alcohol, and to investigate the potential for misuse of oral administration of remimazolam in, for example, drug-facilitated sexual assaults.

Materials and Methods

Trial 1: Oral Bioavailability of Remimazolam

Trial Design

This randomised, open-label, phase I trial was conducted to determine the absolute oral bioavailability of remimazolam. A total of 14 healthy volunteers (at least five of each sex) aged 18–55 years, weighing ≥ 50 kg with a body mass index (BMI) of 18.0–32.0 kg/m2 were recruited. Each subject received oral remimazolam 0.14 mg/kg and intravenous remimazolam 0.025 mg/kg under fasting conditions in a cross-over design, allowing for a washout period of at least 24 h between administrations. Volunteers were asked to abstain from alcohol, caffeine, and xanthine-containing beverages or food (e.g. coffee, tea, cola, chocolate, energy drinks) during the trial.

The intravenous dose of 0.025 mg/kg was selected because it produced measurable plasma concentrations of remimazolam and its main metabolite CNS7054 but was devoid of sedative effects [13]. The oral dose was selected based on the expectation of oral bioavailability to be between ~ 10% (results of non-clinical study in rabbits) and, as a worst-case assumption, 100%. Since 0.28 mg/kg (20 mg intravenous bolus in a person weighing 70 kg) was considered the highest safe intravenous dose and hence the highest oral dose to be given in case of ~ 100% bioavailability, 0.14 mg/kg (half that dose), was selected as a precautionary measure.


Blood samples for pharmacokinetic assessments (2 mL) were taken at pre-determined timepoints: pre-dose, 2, 5, 15, 30, and 45 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 h post-dose using an intravenous line dedicated for pharmacokinetic sampling. Bioanalysis of remimazolam (method range 2–2000 ng/mL) and CNS7054 (method range 20–20,000 ng/mL) in human plasma was carried out via high-performance liquid chromatography analyses with tandem mass spectrometry detection using a validated bioanalytical method. Linearity (correlation coefficient) of the method was > 0.9963 for remimazolam and 0.9964 for CNS7054. Within-run precision was < 6.6% and < 5.1, and accuracy was 99.7–113.6 and 85.2–107.7 for remimazolam and CNS7054, respectively. Pharmacokinetic variables were derived from the plasma concentrations and non-compartmental analyses of plasma concentration–time data for remimazolam and its metabolite (CNS7054). Safety measurements, including adverse events, were documented. Demographic data (age, sex, race, and ethnicity) and medical histories were collected at screening.

The oral bioavailability determined in this trial was used to guide dose selection in trial 2.

Trial 2: Pharmacokinetic/Pharmacodynamic (PK/PD) Effects of Oral Remimazolam with and Without Alcohol

This two-part trial investigated the PK/PD effects of higher doses of oral remimazolam in healthy female volunteers aged 21–45 years, weighing ≥ 50 kg with a BMI of 18‒33 kg/m2, and moderate drinking habits. These were defined as more than two drinks/week and ≤ 14 drinks/week (one drink equals approximately 12 oz/350 mL of beer, 5 oz/150 mL of wine, or 1.5 oz/45 mL of spirits). Female subjects were selected because they represent the population at greatest risk for victimization in drug-facilitated sexual assaults. In addition, females have a slower alcohol metabolism, so the effects of remimazolam may last longer in the presence of alcohol. To ensure the absence of pharmacodynamic interactions with any other CNS depressant, apart from investigated alcohol in part 2 of the trial, volunteers who tested positive for opiates, methadone, cocaine, amphetamines (including ecstasy), cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol in drug and alcohol screening were excluded from the trial.

Trial Design

Part 1: Minimally Biological Active Dose of Oral Remimazolam

This was an open-label, dose-ascending trial to find the minimal biologically active dose (MBAD) of oral remimazolam. Up to 21 healthy female volunteers were to be recruited and allocated to five sequential groups of ascending oral remimazolam doses: 60 mg (n = 3), 140 mg (n = 3), 240 mg (n = 5), 360 mg (n = 5), and 480 mg (n = 5). A minimum 10-h fast was required before administration of trial drug.

MBAD, in the context of this trial, was defined as the lowest dose that affects consciousness and was identified using the modified observer’s assessment of alertness/sedation (MOAA/S) scale from 0 (deeply sedated) to 5 (fully alert). MBAD was characterised by occurrence of MOAA/S < 3 in at least two of three subjects in the 60/140 mg dose groups or at least three of five subjects in the 240/360/480 mg dose groups.

Based on the oral bioavailability results from trial 1, 60 mg was expected to be a safe dose without clear sedative effects so was used as the starting dose in the second trial. An oral dose of 480 mg (corresponding to 24 vials of remimazolam 20 mg drug product) was approximately equivalent to a pharmacologically active intravenous dose of 5 mg and was defined as the maximal dose to be tested in trial 2. Upon each dose group was completed, a safety review committee (SRC), including the investigators, evaluated the available safety and pharmacodynamic data and decided whether it was safe to escalate to a higher dose. The dose-stopping criteria are described in electronic supplementary material (ESM) 1.

A dose of two levels below the MBAD was to be the starting dose in part 2, so the subjects’ safety could be ensured in case the sedative effects of remimazolam were augmented by alcohol. If no MBAD was identified based on the results of part 1, the doses used in part 2 were to be determined by the SRC but not to exceed 480 mg.

Part 2: Effects of Alcohol on the PK/PD Profile of Oral Remimazolam

This was a randomised, double-blind, placebo-controlled trial to evaluate the effects of alcohol on the PK/PD of oral remimazolam. Up to three escalating doses of remimazolam were to be investigated; as in part 1, the SRC was to make decisions about dose escalation (dose-stopping criteria are described in ESM 1). With each oral remimazolam dose, 12 healthy female volunteers were to be recruited. Subjects were randomised to a treatment sequence consisting of five treatments: remimazolam, remimazolam + 5% v/v alcohol, remimazolam + 15% v/v alcohol, remimazolam + 40% v/v alcohol, and placebo + 40% v/v alcohol in a five-way cross-over design. A minimum 10-h fast and a minimum 24-h washout were scheduled between consecutive treatments to avoid possible carryover effects. Treatments were administered as a “first drink” (125 mL apple juice, cinnamon/apple cider with or without alcohol) and a “second drink” (50 mL water containing remimazolam or placebo and the bitter agent BITREX® to mask the remimazolam taste). The “first drink” was to be consumed within 5 min and the “second drink” immediately thereafter.

As results of part 1 did not reveal an MBAD, the SRC chose oral remimazolam 360 mg as a starting dose for part 2. Upon completion of the investigation of the 360 mg dose, the SRC decided not to escalate to 480 mg because the risk would outweigh any potential benefit from dose escalation. The trial was therefore terminated.

Both parts 1 and 2 comprised three trial visits: an outpatient screening visit, a 3-day (part 1) or 7-day (part 2) inpatient treatment visit, and a follow-up/end-of-trial visit conducted via telephone.

The design of trial 2 is summarized in a flow chart in the ESM.


Pharmacokinetic assessments were conducted as described in trial 1. The bioanalytical method used in trial 1 was revalidated for this trial. The main difference was the use of isopropyl alcohol instead of methanol as the precipitation agent.

Pharmacodynamic assessments included an alertness/drowsiness visual analogue scale (VAS; 0 = very drowsy, 100 = very alert), the MOAA/S, a Paired Associates Learning Test (PAL), and a Reaction Time Test (RTI). The alertness/drowsiness VAS, PAL, and RTI were recorded using the software CANTAB (Cambridge Cognition). These pharmacodynamic parameters reflect psychomotor effects such as level of sedation, cognitive functions, and memory [14, 15].

As in trial 1, demographic data (ethnicity, age, BMI) were collected at screening. All subjects in part 1 and 2 were females.

Trial 1 was carried out in November 2015 and trial 2 from May to August 2017. Both trials were conducted in the PRA Early Development Services clinical site in Utah, USA. Both trials were carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). The trial 1 protocol was approved by the Midlands Independent Review Board and the trial 2 protocol was approved by the Schulman Independent Review Board. Informed consents were obtained from all participants.

Statistical Analyses

The pharmacokinetic parameters for remimazolam and CNS7054 were estimated using non-compartmental methods with Phoenix® WinNonlin®, version 6.3. The plasma pharmacokinetic parameters were estimated from the concentration–time profiles for the pharmacokinetic population. The relative bioavailability of oral versus intravenous formulations of remimazolam was calculated using the ratio and 90% confidence interval (CI) of geometric means for maximum observed plasma concentration (Cmax), area under the curve (AUC)0–t, and AUC0–inf. Actual body weights of participants were used for calculating all pharmacokinetic parameters. Pharmacodynamic results and changes from pre-dose were summarised by treatment and scheduled time point using descriptive statistics.



In trial 1, 14 of 30 screened healthy volunteers were enrolled. The majority of subjects were White (n = 13), one subject was American Indian or Alaska Native, and four were of Hispanic or Latino ethnicity. All subjects were included in the pharmacokinetic and the safety populations (Fig. S1 in the ESM). Enrolled participants were aged 20–52 years with equal sex distribution and a BMI ranging between 19.2 and 31.8 kg/m2. Participants’ weight ranged between 50 and 103.2 kg.

In part 1 of trial 2, 21 healthy females were enrolled, the majority of whom were White (n = 20) and not of Hispanic or Latino ethnicity (n = 17). Two of these did not complete the trial but were not excluded from the PK/PD or safety population (one subject was lost to follow-up, and one subject withdrew consent, both after completion of dosing). In part 2, 11 healthy females were enrolled (all White and not of Hispanic or Latino ethnicity); one of those did not complete the trial (withdrew consent before completion of the last dosing) and was excluded from the pharmacodynamic population but not from the pharmacokinetic or safety population (Fig. S1 in the ESM). Participants’ age ranged from 21 to 40 years in part 1 and from 25 to 41 years in part 2 with similar BMI (19.4–32.6 kg/m2).

Pharmacokinetics of Remimazolam

Table 1 and Fig. 1 present the pharmacokinetic analyses of remimazolam and its inactive metabolite (CNS7054) as assessed in trial 1 (intravenous dose 0.025 mg/kg corresponding to 1.25‒2.58 mg; oral dose 0.14 mg/kg corresponding to 7.00‒14.4 mg) and in part 1 of trial 2 (oral doses 60, 140, 240, 360, and 480 mg).

Table 1 Pharmacokinetic profile of oral and intravenous remimazolam and its metabolite (results of trial 1 and part 1 of trial 2)
Fig. 1
figure 1

Box and whisker plot including individual value plot of remimazolam AUC0–t and Cmax versus remimazolam and alcohol dose (results of trial 2). Box plots show 25–75 percentile and median values. Whisker plots indicate min and max values. AUC area under the curve, Cmax maximum observed plasma concentration, EtOH alcohol

The Cmax was higher for intravenous than for all oral doses except the highest (480 mg), which had reached plasma levels comparable to intravenous doses (92.9 vs. 94.6 ng/mL, respectively). As the oral dose increased eightfold (from 60 to 480 mg), mean Cmax, AUC0–last, and AUC0–inf increased 5.7-, 10.6-, and 6.4-fold, respectively. Median time to reach Cmax (tmax) following oral administration was short, ranging between 15 and 30 min, independent of dose. After reaching Cmax, concentrations decreased rapidly until they were no longer quantifiable at 1.5–4 h, depending on dose (Fig. S2 in the ESM). Plasma clearance was rapid, with a mean half-life (t½) ranging from 20 to 40 min, and increased only slightly in relation to oral doses. Mean apparent oral clearance (CL/F) and apparent volume of distribution during the terminal phase (Vz/F) all increased with oral doses and were markedly greater than with the intravenous dose.

For the metabolite CNS7054, Cmax, AUC0–last, and AUC0–inf were all considerably greater than those of the parent. These parameters also increased as the oral dose increased from 60 to 480 mg by 9.2-, 12.3-, and 12.1-fold, respectively. Median tmax was short, ranging from 30 to 60 min. For the higher oral doses of remimazolam (60–480 mg), the tmax of the metabolite occurred only 15–30 min after the tmax of the parent. The mean half-life of the metabolite was greater than that of the parent, ranging from 1.75 to 2 h, independent of dose.

Pharmacokinetics of Oral Remimazolam with Alcohol

Tables 2 and 3 and Fig. 1 present the pharmacokinetic results from part 2 of trial 2 (oral doses: remimazolam 360 mg, remimazolam 360 mg + 5% v/v alcohol, remimazolam 360 mg + 15% v/v alcohol, remimazolam 360 mg + 40% v/v alcohol, and placebo + 40% v/v alcohol). Table 2 presents the descriptive statistics and Table 3 the statistical analysis.

Table 2 Pharmacokinetic parameters for remimazolam and its metabolite in plasma after oral administration of remimazolam 360 mg with and without alcohol (results of trial 2)
Table 3 Statistical analysis of the effect of alcohol on systemic exposure to remimazolam and CNS7054

Alcohol increased the exposure to remimazolam. As the amount of alcohol increased from no alcohol to 5%, 15%, and 40%, the Cmax of remimazolam increased 1.2-, 1.5-, and 2.1-fold, respectively. Over the same dose range, AUC0–last increased 1.1-, 1.6-, and 2.0-fold, and AUC0–inf increased 1.1-, 1.6-, and 1.9-fold, respectively (Table 3). The median tmax was short, ranging between 15 and 30 min, independent of the alcohol dose, and was similar to that obtained with remimazolam doses of 60–480 mg without alcohol (results of part 1). After reaching Cmax, concentrations decreased rapidly until they were no longer quantifiable at 4 h (Fig. S2 in the ESM). Plasma clearance of remimazolam was also rapid, with mean t½ ranging from 30 to 40 min and independent of alcohol dose. However, the CL/F and Vz/F of remimazolam decreased as the amount of alcohol increased.

The mean Cmax, AUC0–t, and AUC0–inf of the metabolite increased relative to the amount of added alcohol, but the degree of change was very modest. As co-administered alcohol concentrations increased from 0 to 5%, 15%, and 40%, Cmax increased by 1.0-, 1.1-, and 1.1-fold; AUC0–t increased by 1.0-, 1.1-, and 1.2-fold; and AUC0–inf increased by 1.0-, 1.1-, and 1.3-fold, respectively. Median tmax was approximately 1 h with 0% v/v or 5% v/v alcohol and increased to 1.5 h with 15% v/v or 40% v/v alcohol. Median tmax for CNS7054 occurred after approximately 30–60 min after the tmax for the parent. The half-life of the metabolite (1.86–2.09 h) was also somewhat greater than that of remimazolam and independent of the amount of alcohol.

Oral Bioavailability of Remimazolam

The absolute bioavailability of oral remimazolam was very low: 2.2% (90% CI 0.015–0.032) based on AUC0–t and 1.2% (90% CI 0.008–0.017) based on Cmax (Table 4). In contrast, the oral bioavailability of the metabolite (> 100%) was considerably greater than that of the parent drug, indicating that low oral bioavailability of remimazolam was an effect of extensive first-pass metabolism and not of low absorption.

Table 4 Oral bioavailability of remimazolam and its metabolite

Pharmacodynamics of Oral Remimazolam

Table 5 presents the results of the pharmacodynamic assessments from part 1 of trial 2 with five oral remimazolam doses tested: 60, 140, 240, 360, and 480 mg. No pharmacodynamic assessments were performed in trial 1.

Table 5 Selected descriptive statistics for main pharmacodynamic parameters of oral remimazolam (results of part 1 of trial 2)

Mean alertness/drowsiness VAS minimum effect (Emin) showed a mild dose-dependent drowsiness up to 240 mg, with a plateau at higher doses. Similarly, sedation was not achieved with the two lowest doses (60 and 140 mg) of remimazolam (MOAA/S = 5), whereas one subject each treated with 240 and 360 mg reported an MOAA/S score of 4 at 15 min postdose and one subject treated with 480 mg reported an MOAA/S score of 3 at 45 min postdose. Results of the PAL and RTI 5-choice tests suggested that subjects’ learning performance and reaction time were not affected by oral remimazolam.

As a result, an MBAD of oral remimazolam (defined as MOAA/S < 3 in at least two of three subjects in the 60/140 mg groups or at least three of five subjects in the 240/360/480 mg groups) was not identified in this part of the trial.

Pharmacodynamics of Oral Remimazolam with Alcohol

Table 6 presents the pharmacodynamic results from part 2 of trial 2 (oral doses: remimazolam 360 mg, remimazolam 360 mg + 5% v/v alcohol, remimazolam 360 mg + 15% v/v alcohol, remimazolam 360 mg + 40% v/v alcohol, and placebo + 40% v/v alcohol).

Table 6 Selected statistics for main pharmacodynamic parameter endpoints of oral remimazolam 360 mg co-administered with alcohol (results of part 2 of trial 2)

Drowsiness (VAS < 50) was observed in all five groups; the greatest alertness/drowsiness VAS Emin was in the placebo + 40% v/v alcohol group, followed by the remimazolam alone group and the three remimazolam + alcohol groups. No trend of alcohol dose dependency was observed. Mean MOAA/S scores of 4.13 or 4.50 indicated almost no sedative effects. One subject had an MOAA/S of 2 following treatment with remimazolam alone and an MOAA/S of 3 following treatment with remimazolam + 15% v/v alcohol. Another subject had an MOAA/S of 2 and an MOAA/S of 1 at two time points after remimazolam + 40% v/v alcohol. In line with these results, subjects’ learning performance seemed to be slightly worse in the remimazolam + alcohol groups than in the remimazolam alone or alcohol alone groups. However, the reaction time was not increased when remimazolam was co-ingested with alcohol.


There were no fatal, serious, or severe adverse events, nor did any adverse events lead to discontinuation of study drug in either trial. Almost all subjects reported at least one treatment-emergent adverse event (12/14 [85.7%] in trial 1, 19/21 [90.5%] in part 1 of trial 2, 11/11 [100%] in part 2 of trial 2). Most of these were transient and of mild severity.

Adverse events of interest in trial 1 are presented in Table S1 in the ESM, and abuse-related adverse events in trial 2 are presented in Table S2 and Table S3 in the ESM. In general, more adverse events were reported in part 2 of trial 2 than in trial 1 or part 1 of trial 2. The most common adverse event was somnolence (21.4% in trial 1, 47.6% in part 1 of trial 2, 100% in part 2 of trial 2). All somnolence adverse events were of mild severity in trial 1 and part 1 of trial 2, whereas about 50% were of moderate severity in part 2 of trial 2, in line with the observed additive effects between remimazolam and alcohol.

There were no important changes in laboratory parameters in any trial. No clinically important changes in vital signs were reported in trial 1. In both parts of trial 2, although clinically important changes in vital signs were observed in some subjects, there were no meaningful or remimazolam/alcohol dose-dependent trends in blood pressure, heart rate, respiratory rate, or blood oxygen saturation changes. No subjects required airway intervention.


The pharmacokinetic results of trial 1 and part 1 of trial 2 indicate that remimazolam is completely absorbed from the gastrointestinal system but then undergoes rapid and extensive first-pass metabolism following oral administration, regardless of dose level, resulting in a markedly low oral bioavailability (2.2% based on AUC0–t and 1.2% based on Cmax). The oral bioavailability of remimazolam can be considered negligible compared with that of other benzodiazepines (midazolam 31‒72% [16], flunitrazepam 50% [17], diazepam > 90% [18], and lorazepam 91–95% [19]).

Oral remimazolam is metabolized and absorbed considerably faster than other benzodiazepines: t½ remimazolam 0.3–0.7 h versus midazolam 1.7–3.5 h, lorazepam 8–15 h, diazepam 30 h, and flunitrazepam 15–30 h; tmax remimazolam 15‒30 min versus midazolam 30‒80 min, lorazepam 2 h, diazepam 1 h, and flunitrazepam 0.6 h [20,21,22]. Another study indicated that the elimination half-life of short-acting benzodiazepines ranges between 1 and 12 h following oral administration [10], making remimazolam ultra short acting. Indeed, remimazolam was designed to undergo rapid hydrolysis by esterase enzymes (mainly localized in the liver), thereby offering more rapid and predictable onset and offset of action than other available benzodiazepines [1].

Of note, the pharmacokinetic results of part 2 of trial 2 demonstrated that alcohol did not inhibit the first pass metabolism of remimazolam, even though remimazolam systemic exposure increased proportionally with the co-ingested alcohol amount, and it doubled after remimazolam 360 mg + 40 v/v alcohol, consistent with the known effect of alcohol as an inhibitor of CES1. Nevertheless, remimazolam was still extensively metabolized and disappeared from plasma rapidly, even in the presence of alcohol. Independent of alcohol dose, mean t½ ranged from 20 to 40 min and median tmax from 15 to 30 min, similar to observations at remimazolam 60–480 mg doses without alcohol. Only the formation of the pharmacologically inactive metabolite CNS7054 appeared to be delayed slightly, as the median tmax extended to 1‒1.5 h, but the t½ of 1.86‒2.09 h was comparable to the 1.75‒2 h for the 60‒480 mg doses without alcohol, indicating that alcohol has little to no impact on elimination of the metabolite. Given the negligible oral bioavailability of remimazolam, alcohol-induced increases in exposure can still be considered insignificant, as one can speculate minor increases in oral bioavailability (two times, from approximately 1‒2% to approximately 2‒4%). Interpretation of these results suffers to some extent from the need to use the bioavailability results from trial 1, where different doses were used, as no intravenous arm was present in trial 2. Nevertheless, these extrapolations could be considered conservative, as bioavailability was more likely to go down with increasing oral doses in trial 2.

In line with its pharmacokinetic profile, the sedative effects of oral remimazolam are also limited. In part 1 of trial 2, even the highest oral dose of remimazolam (480 mg) did not appear to impair subjects’ alertness, learning performance, or reaction time. These results are in line with the recently published PK/PD model [23], where the half-maximal effective concentration for an MOAA/S score of 4 was approximately threefold higher than the Cmax reported in this trial. The intravenous dose used in the phase III clinical trials for induction of procedural sedation is 5 mg, almost 100-fold lower. In part 2 of trial 2, even though the systemic exposure to remimazolam was increased in the presence of alcohol, changes in pharmacodynamic sedative effects were modest compared with remimazolam alone. Only one of ten female subjects attained a significant level of sedation (i.e. MOAA/S of 1). As such, these pharmacodynamic effects were not adequately predictable and reliable for use in drug-facilitated sexual assaults.

The remimazolam drug product for intravenous administration is supplied in 20 mg vials; therefore, to achieve the dose level tested in part 2 of trial 2 (360 mg), as many as 18 vials of trial drug would be needed. Importantly, remimazolam has a distinct bitter taste, which is difficult to mask and would make it unsuitable for covert use in drug- facilitated sexual assaults.


Collectively, the oral bioavailability of remimazolam is negligible and the pharmacodynamic assessment of alcohol and remimazolam combinations shows no potential for its use in drug-facilitated sexual assaults.